Sotabase

Career

· Research Intern, NVIDIA2021–
· PhD in Computer Science, UC Berkeley2021–

Publications (27)

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
The Lancet · 2015
553
cited
Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses
Science Translational Medicine · 2012
283
cited
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial
EClinicalMedicine · 2020
229
cited
Tolerability of intramuscular and intradermal delivery by CELLECTRA® adaptive constant current electroporation device in healthy volunteers
Human Vaccines & Immunotherapeutics · 2013
81
cited
The Influence of Universal Face Mask Use on Endophthalmitis Risk after Intravitreal Anti–Vascular Endothelial Growth Factor Injections
Ophthalmology (Rochester, Minn.) · 2021
38
cited
Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100
Molecular Therapy: Oncolytics · 2016
35
cited
Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure
medRxiv · 2021
34
cited
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
Journal for ImmunoTherapy of Cancer · 2016
20
cited
Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals.
Molecular Therapy · 2015
19
cited
Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids) + INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and immunogenicity results
Journal of Immunotherapy for Cancer · 2015
14
cited
Safety, bioavailability, and pharmacokinetics of VGX‐1027—A novel oral anti‐inflammatory drug in healthy human subjects
Clinical pharmacology in drug development · 2016
13
cited
A functional genomics screen identifying blood cell development genes in Drosophila by undergraduates participating in a course-based research experience
G3 · 2021
12
cited
Study of hTERT and IL-12 DNA immunotherapy using electroporation in patients with solid tumors after definitive surgery and adjuvant therapy.
2015
8
cited
A clinical trial for the safety and immunogenicity of a DNA-based immunotherapy in men with biochemically (PSA) relapsed prostate cancer.
2017
6
cited
DNA vaccine VGX-3100 with electroporation induces regression of cervical intraepithelial neoplasia 2/3 and clears HPV infection with robust T cell responses: results of a randomized, double-blind, placebo-controlled Phase II trial
Journal of Immunotherapy for Cancer · 2014
3
cited
Integrated Manufacture of Exoskeleton and Sensing for Folded Millirobots
3
cited
790PDSafety and immunogenicity of a DNA-vaccine immunotherapy in men with biochemically (PSA) relapsed prostate cancer
2017
2
cited
571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster
Open Forum Infectious Diseases · 2021
1
cited
Boosting of cellular and humoral immune responses to HPV16/18 antigens by VGX-3100: A follow-on phase I trial.
2014
1
cited
Evaluation of an immunotherapeutic DNA-vaccine in biochemically relapsed prostate cancer.
2018
1
cited
Sotabase
Jessica Lee | Researcher Profile | Sotabase | Sotabase